Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2019

28.11.2019 | short review

Biomarkers in renal cell carcinoma

verfasst von: OÄ. Dr. Jasmin Terzic, Univ.-Prof. Dr. med. univ. Thomas Bauernhofer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

We have entered a new era for patients with mRCC with multiple treatment options including VEGF(Vascular Endothelial Growth Factor)-, MET(Mesenchymal-eptihelial Transition)-, AXL(AXL-Rezeptortyrosinkinase)-, mTOR(mechanistic Target of Rapamycin)-targeted TKIs (tyrosinekinaseinhibitors) as well as PD-1(programmed cell death protein 1)-, PD-L1(Programmed cell death 1 ligand)- and CTLA4(cytotoxic T-lymphocyte-associated Protein 4)-targeted IOs and their combinations, respectively. However, the possibility to select patients based on predictive biomarkers for the different treatment options is still lacking. The TCGA (Cancer Genome Atlas) consortium conducted comprehensive analyses of genomic and metabolic features of RCC (renal cell carcinoma) and these findings demonstrated significant differences between the major histological subtypes of RCC like differences in immune signatures and their course of disease. The increasing knowledge on the genomic landscape of RCC supports stratification of patients for targeted therapies. Biomarker development for future therapeutic approaches will require integration of multiple biologic components like PD-L1 expression, tumor-infiltrating lymphocytes and mutations in addition to the prognostic risk scores. However, no single molecular marker has been shown to improve the accuracy of MSKCC (Memorial Sloan Kettering Cancer Center) or IMDC (International Metastatic RCC Database Consortium) prognostic risk scores. Large-scale biomarker-driven prospective trials with consensus methodologies on biomarker assessment and scoring are needed to obtain clinically validated new prognostic and predictive biomarkers as described above. The integration of routinely available parameters and new biomarkers could hold the key for personalized treatment strategies of patients with RCC.
Literatur
2.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. CrossRefPubMed Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. CrossRefPubMed
5.
6.
Zurück zum Zitat Zbar B, Brauch H, Talmadge C, Linehan WM. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327:721–4. CrossRefPubMed Zbar B, Brauch H, Talmadge C, Linehan WM. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327:721–4. CrossRefPubMed
7.
Zurück zum Zitat Latif F, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20. CrossRefPubMed Latif F, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20. CrossRefPubMed
9.
Zurück zum Zitat Varela I, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539–42. CrossRefPubMedPubMedCentral Varela I, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539–42. CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24:749–57. CrossRefPubMedPubMedCentral McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24:749–57. CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Voss MH, Kuo F, Chen D, et al. Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy. J Clin Oncol. 2017;35:4523–4523. CrossRef Voss MH, Kuo F, Chen D, et al. Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy. J Clin Oncol. 2017;35:4523–4523. CrossRef
12.
Zurück zum Zitat Rini BI, et al. Molecular correlates differentiate response to atezolizumab + bevacizumab vs sunitinib. ESMO 2018 Congress; 20 Oct 2018. 2018. Abstract LBA31. Rini BI, et al. Molecular correlates differentiate response to atezolizumab + bevacizumab vs sunitinib. ESMO 2018 Congress; 20 Oct 2018. 2018. Abstract LBA31.
13.
Zurück zum Zitat Choueiri TK, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35:2993–3001 . CrossRefPubMed Choueiri TK, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35:2993–3001 . CrossRefPubMed
14.
Zurück zum Zitat Choueiri TK, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–6. CrossRefPubMed Choueiri TK, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–6. CrossRefPubMed
15.
16.
Zurück zum Zitat Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45. CrossRef Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45. CrossRef
17.
Zurück zum Zitat Brunelli M, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005;18:161–9. CrossRefPubMed Brunelli M, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005;18:161–9. CrossRefPubMed
18.
Zurück zum Zitat Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103–13. CrossRefPubMed Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103–13. CrossRefPubMed
23.
Zurück zum Zitat McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57. CrossRefPubMedPubMedCentral McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57. CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Turajlic S, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009–21. CrossRefPubMed Turajlic S, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009–21. CrossRefPubMed
25.
Zurück zum Zitat Zehir A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13. CrossRefPubMedPubMedCentral Zehir A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13. CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Jilaveanu LB, Shuch B, Zito CR, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. 2014;5:166–72. CrossRefPubMedPubMedCentral Jilaveanu LB, Shuch B, Zito CR, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. 2014;5:166–72. CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Callea M, Genega EM, Gupta M, et al. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. J Clin Oncol. 2014;32(Suppl 4):467. CrossRef Callea M, Genega EM, Gupta M, et al. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. J Clin Oncol. 2014;32(Suppl 4):467. CrossRef
30.
Zurück zum Zitat Alsaab HO, et al. PD‑1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. CrossRefPubMedPubMedCentral Alsaab HO, et al. PD‑1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognosticstratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–40. CrossRefPubMed Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognosticstratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–40. CrossRefPubMed
33.
Zurück zum Zitat Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54. CrossRefPubMed Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54. CrossRefPubMed
35.
Zurück zum Zitat Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9. CrossRef Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9. CrossRef
Metadaten
Titel
Biomarkers in renal cell carcinoma
verfasst von
OÄ. Dr. Jasmin Terzic
Univ.-Prof. Dr. med. univ. Thomas Bauernhofer
Publikationsdatum
28.11.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00549-0

Weitere Artikel der Ausgabe 4/2019

memo - Magazine of European Medical Oncology 4/2019 Zur Ausgabe